ORLANDO, Fla.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI) today announced independent researchers from leading universities in Germany, Austria, Italy, and Sweden, reported early positive results from the first Phase 2 clinical trial evaluating treatment-naïve patients with follicular non-Hodgkin’s lymphoma (NHL) treated with ZEVALIN (ibritumomab tiuxetan) injection for intravenous use as a monotherapy. This trial differed from earlier ZEVALIN trials in NHL in that patients were treated with ZEVALIN first-line, without the use of upfront chemotherapy. The data were presented at an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
